Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,214 GBX | -0.26% | -0.60% | +15.00% |
10:04am | ASTRAZENECA : UBS reiterates its Sell rating | ZD |
05-14 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.00% | 239B | |
+31.41% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+10.22% | 210B | |
-6.99% | 200B | |
+8.12% | 167B | |
-1.42% | 161B | |
+1.41% | 124B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Transcript : AstraZeneca PLC, H1 2020 Earnings Call, Jul 30, 2020